As in other hematological malignancies, the achievement of a complete remission (CR) is important in multiple myeloma but is still based on common cytological and electrophoretic criteria. In this report, we studied 14 patients who achieved an apparent CR following high-dose therapy using fluorescence in situ hybridization (FISH) analysis. Although the results were difficult to interpret in two patients, 12 of 14 patients had unequivocal persistence of abnormal plasma cells in their bone marrow. Our results suggest that only a few patients, if any, are in true CR following one course of high-dose therapy and are in favor of post-transplantation treatments.
Introduction
Complete remission (CR) in multiple myeloma (MM) is commonly defined by achievement of bone marrow plasmacytosis Ͻ5% and disappearance of the M-component in serum and urine. Although the achievement of a complete remission is considered as a strong prognostic factor in high-dose therapy protocols, the current parameters used to define remission are probably insufficient. 1 Eventually, nearly all patients will relapse after the achievement of this so-called complete remission, favoring the fact that the abnormal clone is quiescent rather than is eliminated. Recent data demonstrate that nearly all patients display cytogenetic changes within their plasma cells. 2 So, cytogenetic analysis of bone marrow plasma cells (BMPC) could help to define complete remission, but conventional cytogenetics is hampered by very low numbers of BMPC. By contrast, fluorescence in situ hybridization (FISH) might be an adequate technique, as previously shown in MM, 3 monoclonal gammopathy of undetermined significance, 4 and circulating plasma cells. 5 In this study, we evaluated interphase fluorescence in situ hybridization (FISH) for the detection of minimal residual disease in 14 MM patients who achieved an apparent complete remission after highdose therapy.
Patients and methods

Patients
The study concerns 14 patients with multiple myeloma diagnosed in our center according to Durie 6 between January 1992 and February 1995. These were consecutive patients in 7 Six patients were male and median age was 54 years (range 38-65). The M-component was G kappa in four patients, G lambda in four patients, A lambda in four patients and lambda light chain in two patients. Staging was IA (symptomatic) in two patients, IIA in one patient, IIIA in eight patients and IIIB in three patients. After treatment (2-21 months, median 4.5 months), electrophoresis and immunofixation of serum and urine were performed to assess biochemical remission at the time of bone marrow FISH analysis. Bone marrow plasmacytosis ranged from 0.1% to 3.5% (median 0.6%, 1000 cells enumerated). No patient had a detectable M-component on electropheresis. Nevertheless, only four patients had a negative immunofixation (three patients with an A lambda isotype and one patient with a lambda light chain isotype). All patients had cytogenetic abnormality identified at diagnosis either by conventional cytogenetics (6 patients) or after fluorescence in situ hybridization (FISH) (8 patients). Conventional cytogenetic analyses were performed as previously reported, 8 and interphase FISH was performed at diagnosis and after remission as follows.
Interphase FISH study
Mononuclear cell separation of EDTA anticoagulated bone marrow (sternal bone or iliac posterior crest) was performed by density gradient centrifugation (density = 1.077; MSL; Eurobio, Les Ulis, France), cells centrifuged and slides stored at −20°C until use. For all patients tested after treatment, bone marrow samples were aspirated by the same day as for biochemical studies. For the specific study of plasma cells we used interphase FISH coupled to immunological detection of monotypic light chain. Biotinylated probes for chromosome Nos 3, 7, 8, 9, 11, 15, 13/21 and X were all purchased from Oncor (Gaithersburg, MD, USA). Cytocentrifuge slides were fixed in cold acetone (5 min), in 4% paraformaldehyde in phosphate-buffered saline (PBS; pH 7.40), rinsed and allowed to dry for 15 min. The step corresponding to immunostaining of BMPC was performed as follows. After rehydratation of slides with PBS, diluted (1/100) rabbit polyclonal anti-human light chains (either or ) antibody, directly labeled with FITC (Dako, Glostrup, Denmark), was applied for a brief period (5 min); next, slides were rinsed with PBS, air dried, and dehydrated in graded alcohols. The step corresponding to the hybridization of DNA probe was done as follows. Slides were denaturated for 5 min at 72°C in 70% formamide solution (in 2ϫ sodium saline citrate); 10 l of hybridization mixture was applied next (0.5 l of biotin-labeled probe in 9.5 l of Hybrisol VI (Oncor), denaturation for 2 min at 72°C), coverslipped and sealed with rubber cement. After one night of hybridization at 37°C, amplification of the biotinylated probe was performed using successive layers of Texas red avidin (Vector, Burlingame, CA, USA), biotinylated anti-avidin antibody (Vector), and Texas red avidin once again, as previously described. 4 Slides were next counterstained with 4,6-diaminophenyl indole (DAPI) and analyzed under a fluorescence microscope. Trisomy or monosomy were ascertained when Ͼ8% or Ͼ15% plasma cells exhibited three or one signal, respectively (except for 13/21 probe). All patients were tested with two or three different probes. In each patient at least 100 and 50 cells were enumerated at diagnosis and after treatment, respectively.
Results and discussion
Results of the cytological and cytogenetic analyses, as well as clinical course of the patients are presented in Table 1 . Twelve patients who had either trisomy of monosomy within their bone marrow plasma cells (BMPC) at diagnosis exhibited the same anomaly within their BMPC after treatment and were thus not in complete remission. In these patients, trisomic and monosomic cells were clearly over the thresholds, ranging from 12 to 57% and 17 to 71%, respectively. All these results were concordant using either two (six patients) or three (six patients) different probes. In the last two patients, the remission status was as follows: one patient had −3, +11 at diagnosis and −3 (33%) but disomy for chromosome 11 after autograft, and one patient could only be tested with the 13/21 probe (54% abnormal cells). Eventually, at least 12 of 14 patients had unequivocal persistence of an abnormal plasma cells clone within their bone marrow.
In this study we used a modified FISH technique and not a polymerase chain reaction analysis. Although less sensitive, it was sufficiently powerful, however, to clearly detect persistent cytogenetic abnormalities within the BMPC from most (12 of 14) patients tested after intensive treatment. Interphase and metaphase FISH have been demonstrated to be sensitive methods for detecting minimal residual disease in leukaemias and lymphomas. [9] [10] [11] [12] [13] In multiple myeloma, a recent report using interphase FISH with a chromosome 9 centromeric probe detected a persistent trisomy 9 in one of four patients after autograft, two of three bone marrow collections and one of 10 peripheral blood stem cell transplants.
14 Although the gain of chromosome 9 is one of the most frequent cytogenetic abnormalities found in MM, a higher rate of positivity may be expected using a patient-specific panel of probes. Molecular monitoring of minimal residual disease (MRD) in MM has also been reported. In a recent report of Corradini et al, 15 a PCR detection of MRD was performed, demonstrating molecular remission in only 8% of autografted patients in apparent complete remission using usual criteria. These latter molecular results are in line with our FISH results. In our study, the persistent abnormal plasma cells could theoretically represent: (1) residual tumor cells that are viable but incapable of replication as a result of the intensive treatment; (2) premalignant plasma cells that share a karyotype and clonal immunoglobulin phenotype with the malignant tumor cell; (3) residual tumor cells that retain the capability to replicate and eventually regrow the malignant tumor. This last hypothesis is in agreement with the clinical course of virtually all patients who ultimately relapse. Residual BMPC which share the initial chromosomal abnormalities and could escape the conditioning regimen would likely be involved in the relapse. Indeed, numerous chromosomal changes are usually common between diagnosis and relapse, although sequential clonal evolution at relapse can be observed. 16 In the future, a sequential FISH study at different evolutive phases of the disease would probably be of interest.
The patients reported in our series represent 35% (14/40) of myeloma patients receiving high-dose therapy in the study period in our center. Nine out of these 14 patients relapsed. Six patients are still alive, including two patients in relapse. Three patients (patients 6, 8 and 11) who still had a few demonstrable plasma cells have long survival without progression. Thus, the persistence of a few abnormal plasma cells does not preclude long progression-free survival.
In our opinion, these results show that most if not all of myeloma patients, selected using usual complete remission criteria, are not in complete remission after interphase FISH study, due to the persistence of cytogenetically abnormal BMPC.
